新西兰自然健康产品-药物相互作用评估及编码可行性分析
本研究分析新西兰普通人群在线调查数据,发现992名参与者中38.4%使用自然健康产品(NHP),其中71.1%同时使用常规药物。鱼油、辅酶Q10、姜黄和葡萄糖胺存在潜在相互作用,鱼油与华法林联用被评为「可能导致显著危害」。33.1%的NHP无法用WHODrug编码,NHP编码者间一致性(κ=0.576)低于常规药物(κ=0.911)。
要点
- 38.4%参与者使用NHP,其中71.1%同时使用常规药物。
- 鱼油与华法林联用被评为「可能导致显著危害」。
- 33.1%的NHP无法用WHODrug编码,需标准化编码工具。
核心结论
- NHP与常规药物同时使用普遍,存在潜在不良反应组合。
- 鱼油与华法林相互作用被评为「可能导致显著危害」。
- 当前NHP编码工具不足,需标准化 comprehensive 编码工具。
研究设计与样本
- 基于新西兰NHP使用试点研究数据集的分析。
- 共纳入992名参与者。
- 两名编码者独立分配WHODrug Global代码,用Fleiss Kappa评估一致性。
主要发现
- 381名(38.4%)为当前NHP使用者,报告使用1-18种NHP。
- 271名(71.1%)NHP使用者同时使用常规药物。
- 潜在相互作用涉及鱼油、辅酶Q10、姜黄和葡萄糖胺。
- 33.1%的NHP无法用WHODrug编码。
- 编码一致性:常规药物93.7%,NHP 63.5%;Fleiss Kappa NHP κ=0.576,常规药物κ=0.911。
临床怎么用
- 临床应主动询问患者NHP使用情况,尤其与华法林等药物联用。
- 对鱼油、辅酶Q10、姜黄、葡萄糖胺等NHP保持警惕。
- 编码和记录NHP时需注意标准工具局限性。
局限性
- 数据来自在线市场研究小组的试点研究,非全国代表性样本。
- NHP编码困难可能影响相互作用全面识别。
- 需更大规模全国代表性数据验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Natural health products (NHPs) include complementary/alternative medicines, dietary supplements, nutraceuticals, and traditional medicines. Natural health products are often self-prescribed and used alongside conventional medicines, raising safety concerns. AIMS: This study aims to explore NHP-conventional medicine (NHP-drug) combinations used by respondents in New Zealand (NZ), identify those with the potential to cause NHP-drug interactions, and assesses the feasibility of coding NHPs using the WHODrug dictionary. METHODS: A dataset from a pilot study on NHP use in NZ was analysed. Data on NHP and conventional medicine use were descriptively analysed. Where possible, specific product ingredient lists were verified. Two coders independently assigned WHODrug Global codes to each NHP and conventional medicine. Fleiss' Kappa measured inter-coder agreement. RESULTS: Of 992 participants, 381 (38.4%) were current NHP users, reporting 1-18 NHPs. Among them, 271 (71.1%) used conventional medicines concurrently. Natural health product-drug combinations with potential interactions were found with fish oil, coenzyme Q10, turmeric, and glucosamine. An interaction involving fish oil and warfarin was rated as 'may result in significant hazard.' One-third (33.1%) of NHPs could not be coded using WHODrug. Codability agreement was higher for conventional medicines (93.7%) than for NHPs (63.5%). Fleiss' Kappa indicated moderate agreement for NHPs (κ = 0.576) and very good agreement for conventional medicines (κ = 0.911). CONCLUSION: Substantial concurrent NHP-drug use was identified, including combinations with potential adverse reactions. A larger, nationally representative dataset on NHP exposures in NZ is needed. Current challenges in coding NHPs highlight the need for standardised, comprehensive coding tools in future research for comprehensive analysis. This New Zealand-based study explored the use of natural health products (NHPs) alongside conventional medicines to identify potential interactions. Among 992 participants, 38.4% reported using NHPs, with 71.1% of these individuals also taking conventional medicines concurrently. Combinations with potential interactions, such as fish oil and warfarin, were identified. A notable challenge emerged when categorising NHPs using a standard drug dictionary, as 33.1% of NHPs could not be coded. For products that could be coded, agreement between coders was much higher for conventional medicines (93.7%) than for NHPs (63.5%), highlighting difficulties in applying standardised coding methods to NHPs. The study underscores the need for larger, nationally representative research to better understand NHP use and calls for improved, standardised methods for classifying NHPs. These efforts are essential to reducing the potential risks associated with combining NHPs and conventional medicines.
引用
- Lee EL, Ogle F, Nagra J, et al. Assessing Natural Health Product-Drug Interactions and Coding Feasibility: Analysis of a New Zealand General Population Dataset from an Online Market Research Panel. Drug Saf. 2026. PMID: 42105017. doi:10.1007/s40264-026-01667-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。